Apixaban reduces stroke rates in atrial fibrillation patients with previous stroke or TIA

In a subset of patients that had experienced a previous stroke or transient ischemic attack (TIA), treatment with the investigational drug apixaban resulted in a reduced rate of stroke and systemic embolism compared with warfarin, according to a recent subset analysis of a major clinical trial.

Stroke is the third-leading cause of death in India; approximately 145 out of every 100,000 Indians experienced a stroke between 2005 and 2006, according to a 2010 study. Complications of stoke include death, disabilities such as cognitive and/or physical decline, seizures, dementia, and depression.

In the recently published study of apixaban, researchers at the Department of Neurology at the University of California-San Francisco in San Francisco, California, United States, conducted an analysis of a subset of patients that participated in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial to determine the...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiovascular, Neurology, Neurology Featured 2, Primary Care and tagged , , , , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.